Air Street Capital is a venture capital firm investing in AI-first technology and life science companies.
Portfolio
6
companies
CellVoyant
CellVoyant is a biotechnology company developing artificial intelligence platforms to advance novel stem cell therapies.
Clove
Clove builds a hybrid financial advice platform powered by human expertise and artificial intelligence.
Perceptic
Building an artificial intelligence operating system for pharmaceutical drug development.
Synthesia
Synthesia builds a platform for generating professional video content directly from text using customizable avatars.
V7
V7 develops a data engine platform that automates labeling to build machine learning models.
V7 Labs
V7 Labs provides a computer vision and training data platform for artificial intelligence teams.
Nathan Benaich
Founder and General Partner
Nathan is the founder of Spinout.fyi and general partner at Air Street Capital. He also authors the State of AI Report.
LinkedInThe London-based company raised capital from Accel, Air Street Capital, and Elder Gull to grow its engineering team and scale deployments.
"Too many critical drug development decisions still happen without a complete view of the evidence. Perceptic connects data, context, and decision-making so every insight compounds instead of dying at the next handoff."
Google Ventures led the Series E financing round, which valued the video platform at $4bn.
"Synthesia is a UK success story, creating new jobs and opportunities in this country. It shows that by backing innovators to start, scale and stay in the UK through better access to finance and generous tax reliefs, we can turn the promise of AI into better-paid jobs and long-term growth across the UK."
The London-based fintech startup secured backing from Accel, Kindred Capital, and Air Street Capital to develop its hybrid advisory platform.
"a huge section of society has been failed by the financial advice industry, because it is only able to serve those that are already wealthy."
Octopus Ventures led the seed financing, with participation from Horizons Ventures, Verve Ventures, and Air Street Capital, to commercialise live cell imaging technology.
"University spin-outs like CellVoyant are at the heart of the UK’s thriving biotech ecosystem. CellVoyant sets a new standard in precision and reliability for predicting and controlling stem cell behaviour, which will make cell therapies more accessible to those who need them. We are thrilled to invest into a company that is transforming how patients can benefit from life-changing treatments."
The financing was co-led by Radical Ventures and Temasek to fuel expansion in the United States.
"The next generation of software won’t run on code, it will run on models fueled by training data. We let our clients easily turn human knowledge into AI models, improving the safety and accuracy of AI. This is incredibly powerful, and in the right hands, can literally save lives. If we want to build software that tackles unsolved frontiers in human health, or our climate, this is the only way"
